Tsochatzis Emmanuel A, Fatourou Evangelia, O'Beirne James, Meyer Tim, Burroughs Andrew K
Emmanuel A Tsochatzis, Evangelia Fatourou, James O'Beirne, Andrew K Burroughs, Sheila Sherlock Liver Centre, Royal Free Hospital and UCL Institute of Liver and Digestive Health, London NW3 2QG, United Kingdom.
World J Gastroenterol. 2014 Mar 28;20(12):3069-77. doi: 10.3748/wjg.v20.i12.3069.
Transarterial chemoembolization (TACE) is the first line treatment for patients with intermediate stage hepatocellular carcinoma but is also increasingly being used for patients on the transplant waiting list to prevent further tumor growth. Despite its widespread use, TACE remains an unstandardized procedure, with variation in type and size of embolizing particles, type and dose of chemotherapy and interval between therapies. Existing evidence from randomized controlled trials suggest that bland transarterial embolization (TAE) has the same efficacy with TACE. In the current article, we review the use of TACE and TAE for hepatocellular carcinoma and we focus on the evidence for their use.
经动脉化疗栓塞术（TACE）是中期肝细胞癌患者的一线治疗方法，但也越来越多地用于等待肝移植的患者，以防止肿瘤进一步生长。尽管其应用广泛，但TACE仍然是一种未标准化的操作，在栓塞颗粒的类型和大小、化疗的类型和剂量以及治疗间隔方面存在差异。随机对照试验的现有证据表明，单纯经动脉栓塞术（TAE）与TACE具有相同的疗效。在本文中，我们回顾了TACE和TAE在肝细胞癌中的应用，并重点关注其应用的证据。
